Blueprint Medicines (BPMC) Misses Q3 EPS by 37c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Ovintiv adds 41,000 acres in Permian and Montney deals
- Russia says it could strike UK military targets in response to Kyiv's use of British missiles
Blueprint Medicines Reports Third Quarter 2021 Financial Results
October 28, 2021 7:00 AM EDTCAMBRIDGE, Mass., Oct. 28, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today reported financial results and provided a business update for the third quarter ended September 30, 2021.
"We successfully executed across our entire portfolio in the third quarter, expanding the commercial adoption of AYVAKIT and GAVRETO and further advancing our... More
